Intravaginal Tolterodine Formulation Intended for Overactive Bladder Treatment-Results of a Pharmacokinetic Phase I Pilot Study in Healthy, Postmenopausal Women.
Clin Pharmacol Drug Dev
; 11(1): 80-90, 2022 01.
Article
in En
| MEDLINE
| ID: mdl-34101369
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Urinary Bladder, Overactive
/
Tolterodine Tartrate
Limits:
Female
/
Humans
Language:
En
Journal:
Clin Pharmacol Drug Dev
Year:
2022
Type:
Article
Affiliation country:
Germany